Bone Biologics Corporation completed a private placement with a single healthcare-focused institutional investor in July 2026, generating approximately $3.0 million in gross proceeds. The financing, which includes Series F and G warrants, could provide up to $6.0 million in additional gross proceeds if fully exercised. The company is using the net proceeds to fund clinical trials, maintain patent portfolio, and for working capital. Bone Biologics is a developer of orthobiologic products for spine fusion markets.